Aggressive Non-Hodgkin Lymphoma
Oncology·MeSH: Lymphoma, Follicular
Prevalence
30.0 / 100K
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| jcar017 | Juno Therapeutics, Inc. (JUNO) |
Frequently asked questions
How many drugs are in development for Aggressive Non-Hodgkin Lymphoma?
BioSniper tracks 1 drug in development for Aggressive Non-Hodgkin Lymphoma across 1 company.
How many clinical trials target Aggressive Non-Hodgkin Lymphoma?
There are 1 clinical trial targeting Aggressive Non-Hodgkin Lymphoma tracked by BioSniper.
What is the prevalence of Aggressive Non-Hodgkin Lymphoma?
The estimated prevalence of Aggressive Non-Hodgkin Lymphoma is approximately 30.0 per 100,000 population.
Deep-dive into Aggressive Non-Hodgkin Lymphoma
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis